-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Promoting Minorities in Hematology Oral Presentations St. Charles Ballroom - Malignant Hematology

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Diversity, Equity, and Inclusion (DEI)
Saturday, December 10, 2022: 6:30 PM-8:00 PM
St. Charles Ballroom (Hilton New Orleans Riverside)
ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, the ASH Minority Resident Hematology Award, the ASH Minority Hematology Graduate Award, and the ASH Minority Hematology Fellowship Award program participants. A reception will follow the presentations.
Increasing Transduction Efficiency through Expansion of Stem Cells Via Nicotinamide (NAM)

Amissa Sei

Morehouse School of Medicine, Atlanta, GA
Impact of Tacrolimus on CD19+ CAR T Cell Therapy

Emmanuel Dwomoh

Frank H. Netter MD School of Medicine, North Haven, CT
The RNA Binding Protein Syncrip Is Required for Leukemia Stem Cell Self-Renewal

Florisela Herrejon Chavez, BS

Memorial Sloan Kettering Cancer Center, New York, NY
Hypomagnesemia in Untreated Diffuse Large B-cell Lymphoma

Jennifer Jane Gile, MD

Mayo Clinic, Rochester, MN
Phenotyping Multi-Cytokine Backpack Manufactured CAR T Cells with a 4-1BB Costimulatory Domain

Jonathan Legier, BS

Louisiana State University Health Sciences Center - New Orleans, New Orleans, LA
19S Proteasome Subunits As Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)

Joshua J. Lara, BS

Paul L. Foster School of Medicine, Texas Tech University Health Science Center El Paso, El Paso, TX
Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo

Lynda Villagomez, MD

Department of Pediatrics, Division of Hematology and Oncology, The Ohio State University and Nationwide Children's Hospital, Columbus, OH
Efficacy of Donor Lymphocyte Infusions in Achieving Disease Control in Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation

Naima Hashi, MD

Mayo Clinic, Rochester, MN
The Role of Ikaros (IKZF1) Alterations in B-Acute Lymphoblastic Leukemia

Ruth Wangondu, MD, PhD

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
See more of: Special-Interest Sessions
<< Previous Session | Next Session >>